Ignite Creation Date:
2024-05-06 @ 4:02 PM
Last Modification Date:
2024-10-26 @ 2:02 PM
Study NCT ID:
NCT04840979
Status:
RECRUITING
Last Update Posted:
2023-07-28
First Post:
2021-04-08
Brief Title:
Discovery and Validation of Genetic Variants Affecting Microglial Activation in Alzheimers Disease
Sponsor:
Columbia University
Organization:
Columbia University
Study Overview
Official Title:
Discovery and Validation of Genetic Variants Affecting Microglial Activation in Alzheimers Disease With 11C-ER176
Status:
RECRUITING
Status Verified Date:
2023-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objectives are to validate that a previously identified gene variant influences the proportion of activated microglia PAM and the amount of TSPO binding on PET imaging to identify novel loci that influence PAM and TSPO PET and to understand the functional consequences of gene variants that drive microglial activation in Alzheimers disease
Detailed Description:
While activated microglia have been observed in the vicinity of neuritic amyloid plaques in Alzheimers disease AD there have been no large-scale assessments of microglial activation in aging and neurodegenerative disease The investigators seek to understand the genetic underpinning of microglial responses-particularly the proportion of microglia in a morphologically-defined state of activation-that increase susceptibility to AD so the investigators can develop more targeted forms of immune-based therapies to prevent cognitive decline and progression to dementia The objective is to refine the genetic architecture of microglial activation to validate a previously identified gene variant -- and to identify novel loci -- that influence the proportion of activated microglia The investigators also seek to understand the functional consequences of variants driving microglial activation in AD
The central hypothesis is that identifiable gene variants influence microglial activation and susceptibility to AD The investigators will test this hypothesis by conducting genome-wide analysis and identifying associations between gene variants and microglial activation Microglial activation will be measured in human autopsy tissue ex vivo living human brain using PET imaging in vivo and in monocyte-derived microglia-like cells in situ and in vitro
This genetic study is designed to validate a finding that was discovered in participants with self-reported European-Caucasian ancestry Therefore the study seeks to enroll participants who self-report as white not Hispanic or Latino However if this study is successful the investigators plan to use the methods in this protocol in a future study to identify new genetic variants associated with changes on TSPO PET in a more diverse participant population The investigators intend to use the results from this study to eventually benefit individuals of all racial and ethnic groups
The central hypothesis is that identifiable gene variants influence microglial activation and susceptibility to AD The investigators will test this hypothesis by conducting genome-wide analysis and identifying associations between gene variants and microglial activation Microglial activation will be measured in human autopsy tissue ex vivo living human brain using PET imaging in vivo and in monocyte-derived microglia-like cells in situ and in vitro
This genetic study is designed to validate a finding that was discovered in participants with self-reported European-Caucasian ancestry Therefore the study seeks to enroll participants who self-report as white not Hispanic or Latino However if this study is successful the investigators plan to use the methods in this protocol in a future study to identify new genetic variants associated with changes on TSPO PET in a more diverse participant population The investigators intend to use the results from this study to eventually benefit individuals of all racial and ethnic groups
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| RF1AG070438 | NIH | None | httpsreporternihgovquickSearchRF1AG070438 |